Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kangstem Biotech Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. This distribution indicates that each active matter is being reviewed by a different individual in a different specialized unit. The use of 3 distinct art units suggests that the portfolio covers a range of technical subjects within the Biotechnology & Pharmaceuticals field.
BARRON, SEAN C is the busiest examiner, though he only manages 1 pending office action. This reflects the even distribution of the 3 pending office actions across the various examiners. Practitioners should monitor the 3 distinct examiners to ensure that the arguments presented in each case are consistent with the company's overall strategy. Because each matter is in a different unit, practitioners must be prepared for varying procedural requirements. The outcome of the 1 pending office action under BARRON, SEAN C will provide insight into the examination trends for this specific portion of the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044813 | METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683442 | METHOD FOR TREATING IMMUNE DISEASES USING CALCINEURIN INHIBITOR AND STEM CELLS | BARRON, SEAN C | — |
| 18044813 | METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF | FIEBIG, RUSSELL G | — |
| 18040448 | METHOD FOR PRODUCING HIGHLY FUNCTIONAL ARTIFICIAL ORGANS USING APTAMERS | SHOMER, ISAAC | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1655 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683442 | METHOD FOR TREATING IMMUNE DISEASES USING CALCINEURIN INHIBITOR AND STEM CELLS | BARRON, SEAN C | 1653 | §103 | Final Rejection | — | Pending | Feb 13, 2024 |
| 18044813 | METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF | FIEBIG, RUSSELL G | 1655 | §103§112Other | Final Rejection | — | Pending | Aug 30, 2023 |
| 18040448 | METHOD FOR PRODUCING HIGHLY FUNCTIONAL ARTIFICIAL ORGANS USING APTAMERS | SHOMER, ISAAC | 1612 | §103 | Non-Final OA | — | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial